105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY

Bamco Inc. NY acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 105,000 shares of the company’s stock, valued at approximately $1,589,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ROIV. Jones Financial Companies Lllp boosted its stake in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares during the period. Bessemer Group Inc. increased its stake in Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Aster Capital Management DIFC Ltd increased its stake in Roivant Sciences by 75.8% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock worth $67,000 after buying an additional 1,900 shares during the period. Osaic Holdings Inc. lifted its holdings in Roivant Sciences by 204.2% during the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after buying an additional 3,882 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Roivant Sciences by 16.6% during the 3rd quarter. GAMMA Investing LLC now owns 9,302 shares of the company’s stock valued at $141,000 after buying an additional 1,324 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 1,018,995 shares of the stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the sale, the insider owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. This trade represents a 4.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Frank Torti sold 1,400,000 shares of Roivant Sciences stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $27.42, for a total value of $38,388,000.00. Following the completion of the transaction, the insider owned 13,736,547 shares in the company, valued at $376,656,118.74. This represents a 9.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 7,356,987 shares of company stock worth $184,757,294. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $28.28 on Tuesday. The firm has a 50-day simple moving average of $25.43 and a 200-day simple moving average of $20.87. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $30.33. The firm has a market cap of $20.24 billion, a P/E ratio of -24.17 and a beta of 1.17.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ROIV shares. Guggenheim upped their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Citigroup lifted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. The Goldman Sachs Group increased their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, HC Wainwright lifted their target price on Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.81.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.